Comments
Shares of Lupin are likely to remain active next week, as its subsidiary Lupin Pharmaceuticals Inc has launched ciprofloxacin oral suspension (5g per 100ml and 10g per 100ml), in the US. The oral suspension is used to treat infections caused by susceptible isolates of designated micro-organisms in various conditions and patient populations. Cipro oral suspension had annual US sales of $8.6 million. Lupin has 180 days of marketing exclusivity in the US.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.